Global Indemnity Group reported a Q3 2026 net income of $8.9 million, down from $12.5 million in 2025, with a combined loss ratio of 94.8%. For the nine months, net income rose to $24.2 million from $18.9 million last year. New CEO Jessica Buss, appointed in November, acknowledged a softer Q3 due to maintaining underwriting standards amid competitive pricing cuts but plans to expand distribution and improve efficiency through technology and agency growth. The company maintains strong capital reserves and an AM Best "A" rating, positioning it for sustained growth despite a soft specialty insurance market.
Global Indemnity Group's financial results for Q3 and nine months 2026 provide context for readers. For those following the Financials sector, here is Pluang's market snapshot as of Nov 04, 2026 19:31 WIB: Among 142 priced US Financials stocks tradable on Pluang, 110 rose and 31 fell today. Notable movers include WULF at USD 11.84 with a 1-day change of -5.51% and Pluang order activity heavily skewed to 98% Sell, HSBC at USD 89.00 with a 1-day gain of +5.34% and 82% Buy activity, and LYG at USD 5.25 with a 1-day gain of +5.32%.
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...
The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...
Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...
Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...
